From September 27 to 29, Almaty hosted the ECAT meeting on expanding access to treatment and diagnostics of HIV, viral hepatitis and tuberculosis. The event included a training session – Pavel Khaykin’s report on new treatment of chronic hepatitis delta.
Pavel Khaykin is an infectious disease physician and consultant to the WHO Regional Office. Pavel told the meeting participants about the prevalence and mortality of viral hepatitis delta, and the progression of the disease. Special attention was paid to the review of international clinical guidelines for the diagnosis and treatment of viral hepatitis delta.
Currently, there are only two treatment options available that have shown antiviral efficacy against delta virus hepatitis in randomized controlled clinical trials: bulevirtide and pegylated interferon alpha (PEG-IFN). In his presentation, Paul detailed the clinical trials of bulevirtide, its efficacy and safety, the drug’s mechanism of action, current dosages and dosing regimen.
The event was organized by the International Coalition in Eastern Europe and Central Asia (ITPC EECA) with the support of the Right to Health Coalition (HAC). The meeting was financially supported by ITPC Global, and co-funded by 100% Life Foundation and Alliance for Public Health under the SOS_2.0 project.
A recording of Pavel Khaykin’s report is available at https://www.youtube.com/watch?v=SWvUKcK5Tn4
